Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety

[Guest guest]

Am J Gastroenterol. 2011 Mar 1. [Epub ahead of print]

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic

Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Department of Medicine, The University of Hong Kong, Queen Hospital, Hong

Kong, Hong Kong.

Abstract

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate,

and clinical safety of 3-year continuous entecavir treatment.

METHODS: We determined the cumulative rates of undetectable hepatitis B virus

DNA (HBV DNA) levels (<12 IU/ml), hepatitis B e antigen (HBeAg)

seroconversion, alanine aminotransferase (ALT) normalization, and entecavir

signature mutations (using the sensitive line probe assay) and monitored any

side effects for 222 treatment-naïve chronic hepatitis B (CHB) patients (40.5%

HBeAg positive) on continuous entecavir treatment for 3 years.

RESULTS: The median age and follow-up duration were 45 years and 25.1 months,

respectively. In all, 222, 188, and 101 patients had been followed up for at

least 1, 2, and 3 years, respectively. There were incremental increases in the

rates of HBV DNA undetectability, HBeAg seroconversion, and ALT normalization

reaching to 92.1, 43.9, and 90.4% at year 3, respectively. In all, 100 and 76.5%

of patients with baseline HBV DNA levels < and ≥8 logs copies/ml,

respectively, had undetectable HBV DNA at year 3. The cumulative rate of

entecavir-resistant mutations was 1.2% at year 3. Three patients experienced

virologic breakthrough, one with resistance development, one with subsequent

HBeAg seroconversion, and one with subsequent decline in HBV DNA. Two patients

with baseline rt204I mutations responded to entecavir treatment. There were no

serious adverse events.

CONCLUSIONS: Using very sensitive HBV DNA and viral resistance assays,

continuous entecavir treatment for treatment-naïve CHB patients for 3 years was

associated with >90% chance of undetectable HBV DNA and only 1.2% chance of

emergence of entecavir-resistant mutations.Am J

Gastroenterol advance online publication, 1 March 2011; doi:10.1038/ajg.2011.45.

PMID: 21364549 [PubMed - as supplied by publisher]

[Guest guest]

Am J Gastroenterol. 2011 Mar 1. [Epub ahead of print]

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic

Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Department of Medicine, The University of Hong Kong, Queen Hospital, Hong

Kong, Hong Kong.

Abstract

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate,

and clinical safety of 3-year continuous entecavir treatment.

METHODS: We determined the cumulative rates of undetectable hepatitis B virus

DNA (HBV DNA) levels (<12 IU/ml), hepatitis B e antigen (HBeAg)

seroconversion, alanine aminotransferase (ALT) normalization, and entecavir

signature mutations (using the sensitive line probe assay) and monitored any

side effects for 222 treatment-naïve chronic hepatitis B (CHB) patients (40.5%

HBeAg positive) on continuous entecavir treatment for 3 years.

RESULTS: The median age and follow-up duration were 45 years and 25.1 months,

respectively. In all, 222, 188, and 101 patients had been followed up for at

least 1, 2, and 3 years, respectively. There were incremental increases in the

rates of HBV DNA undetectability, HBeAg seroconversion, and ALT normalization

reaching to 92.1, 43.9, and 90.4% at year 3, respectively. In all, 100 and 76.5%

of patients with baseline HBV DNA levels < and ≥8 logs copies/ml,

respectively, had undetectable HBV DNA at year 3. The cumulative rate of

entecavir-resistant mutations was 1.2% at year 3. Three patients experienced

virologic breakthrough, one with resistance development, one with subsequent

HBeAg seroconversion, and one with subsequent decline in HBV DNA. Two patients

with baseline rt204I mutations responded to entecavir treatment. There were no

serious adverse events.

CONCLUSIONS: Using very sensitive HBV DNA and viral resistance assays,

continuous entecavir treatment for treatment-naïve CHB patients for 3 years was

associated with >90% chance of undetectable HBV DNA and only 1.2% chance of

emergence of entecavir-resistant mutations.Am J

Gastroenterol advance online publication, 1 March 2011; doi:10.1038/ajg.2011.45.

PMID: 21364549 [PubMed - as supplied by publisher]

[Guest guest]

Am J Gastroenterol. 2011 Mar 1. [Epub ahead of print]

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic

Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Department of Medicine, The University of Hong Kong, Queen Hospital, Hong

Kong, Hong Kong.

Abstract

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate,

and clinical safety of 3-year continuous entecavir treatment.

METHODS: We determined the cumulative rates of undetectable hepatitis B virus

DNA (HBV DNA) levels (<12 IU/ml), hepatitis B e antigen (HBeAg)

seroconversion, alanine aminotransferase (ALT) normalization, and entecavir

signature mutations (using the sensitive line probe assay) and monitored any

side effects for 222 treatment-naïve chronic hepatitis B (CHB) patients (40.5%

HBeAg positive) on continuous entecavir treatment for 3 years.

RESULTS: The median age and follow-up duration were 45 years and 25.1 months,

respectively. In all, 222, 188, and 101 patients had been followed up for at

least 1, 2, and 3 years, respectively. There were incremental increases in the

rates of HBV DNA undetectability, HBeAg seroconversion, and ALT normalization

reaching to 92.1, 43.9, and 90.4% at year 3, respectively. In all, 100 and 76.5%

of patients with baseline HBV DNA levels < and ≥8 logs copies/ml,

respectively, had undetectable HBV DNA at year 3. The cumulative rate of

entecavir-resistant mutations was 1.2% at year 3. Three patients experienced

virologic breakthrough, one with resistance development, one with subsequent

HBeAg seroconversion, and one with subsequent decline in HBV DNA. Two patients

with baseline rt204I mutations responded to entecavir treatment. There were no

serious adverse events.

CONCLUSIONS: Using very sensitive HBV DNA and viral resistance assays,

continuous entecavir treatment for treatment-naïve CHB patients for 3 years was

associated with >90% chance of undetectable HBV DNA and only 1.2% chance of

emergence of entecavir-resistant mutations.Am J

Gastroenterol advance online publication, 1 March 2011; doi:10.1038/ajg.2011.45.

PMID: 21364549 [PubMed - as supplied by publisher]

[Guest guest]

Am J Gastroenterol. 2011 Mar 1. [Epub ahead of print]

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic

Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Department of Medicine, The University of Hong Kong, Queen Hospital, Hong

Kong, Hong Kong.

Abstract

OBJECTIVES: We aimed to determine the antiviral potency, viral resistance rate,

and clinical safety of 3-year continuous entecavir treatment.

METHODS: We determined the cumulative rates of undetectable hepatitis B virus

DNA (HBV DNA) levels (<12 IU/ml), hepatitis B e antigen (HBeAg)

seroconversion, alanine aminotransferase (ALT) normalization, and entecavir

signature mutations (using the sensitive line probe assay) and monitored any

side effects for 222 treatment-naïve chronic hepatitis B (CHB) patients (40.5%

HBeAg positive) on continuous entecavir treatment for 3 years.

RESULTS: The median age and follow-up duration were 45 years and 25.1 months,

respectively. In all, 222, 188, and 101 patients had been followed up for at

least 1, 2, and 3 years, respectively. There were incremental increases in the

rates of HBV DNA undetectability, HBeAg seroconversion, and ALT normalization

reaching to 92.1, 43.9, and 90.4% at year 3, respectively. In all, 100 and 76.5%

of patients with baseline HBV DNA levels < and ≥8 logs copies/ml,

respectively, had undetectable HBV DNA at year 3. The cumulative rate of

entecavir-resistant mutations was 1.2% at year 3. Three patients experienced

virologic breakthrough, one with resistance development, one with subsequent

HBeAg seroconversion, and one with subsequent decline in HBV DNA. Two patients

with baseline rt204I mutations responded to entecavir treatment. There were no

serious adverse events.

CONCLUSIONS: Using very sensitive HBV DNA and viral resistance assays,

continuous entecavir treatment for treatment-naïve CHB patients for 3 years was

associated with >90% chance of undetectable HBV DNA and only 1.2% chance of

emergence of entecavir-resistant mutations.Am J

Gastroenterol advance online publication, 1 March 2011; doi:10.1038/ajg.2011.45.

PMID: 21364549 [PubMed - as supplied by publisher]